Thus, even if the work of Xu et al. [35] included thousands of RCC patients, the precise role of CDKN2A mutations (and MTAP mutations) in the response of RCC patients to ICIs (Table 1) remains to be determined. The gene discussed is CDKN2A; the disease is renal cell carcinoma.